Probability of progression-free survival. (A) Adjusted for MRD status and treatment group, (B) cytogenetic risk status, and (C) ISS I and III grouped together, as hazard ratios in these subgroups were numerically identical (C). These curves were constructed according to the results of the Cox model performed on the 366 patients with known MRD status at start of maintenance therapy.